Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sound Bioventures is a venture capital fund founded in 2021 by Casper Breum and Johan Kördel, based in Malmö, Sweden. The firm specializes in investing in private companies that are either entering clinical trials or are already in clinical stages, particularly those developing innovative medicines to address unmet medical needs. Sound Bioventures operates under the Swedish Alternative Investment Funds Managers Act, ensuring compliance and governance in its investment activities.
The firm has a strong emphasis on Scandinavian roots, investing primarily in Europe and the United States. Sound Bioventures has raised a total of €116 million for its first fund, which closed in January 2022. The fund has a diverse LP base, including Novo Holdings, Saminvest, Vækstfonden, and the European Investment Fund (EIF). Currently, the firm manages a portfolio of 10 companies, focusing on therapeutic innovations that are novel and impactful.
Sound Bioventures has established offices in Malmö, Stockholm, and Copenhagen, and is actively involved in the Scandinavian biotech ecosystem. The firm aims to support its portfolio companies through to regulatory approval, providing not only capital but also strategic guidance and access to a wide network of resources.
Sound Bioventures focuses on investing in companies that are entering the clinical stage of drug development. The firm emphasizes therapeutic areas that involve novel medicines, steering clear of incremental innovations, medical devices, digital health, and diagnostics. This focus allows Sound Bioventures to concentrate on specialty therapeutics that address high unmet medical needs, primarily in Europe and the USA.
The firm is open to participating in any private financing round, including pre-seed, seed, seed-plus, Series A, Series B, and Series C. Sound Bioventures seeks to nurture companies until they achieve regulatory approval, providing support throughout the drug development process. The firm particularly values companies with Scandinavian roots, reflecting its commitment to the regional biotech ecosystem.
Sound Bioventures has a diverse portfolio of 10 companies, each focused on innovative therapeutic solutions:
These companies represent a commitment to advancing healthcare through innovative biotherapeutics, with several currently in clinical development stages.
Casper Breum — Managing Partner; previously worked at Lundbeck and Lundbeckfonden Ventures, bringing extensive experience in the biotech sector.
Johan Kördel — Partner; has a background at Novo Nordisk, AstraZeneca, Biovitrum, and Pharmacia, with expertise in drug development and commercialization.
Bibhash Mukhopadhyay — Partner; has experience at Johnson & Johnson and NEA, focusing on investment strategies in the life sciences sector.
Sound Bioventures also employs several principals with backgrounds in life sciences and investment, contributing to the firm's deep expertise in biotech.
To pitch Sound Bioventures, founders should send an email to info@soundbioventures.com. It is essential to include a comprehensive pitch deck that outlines the startup's vision, product details, market potential, and team qualifications. The firm prefers detailed information on the clinical development plan and any existing data supporting the therapeutic approach.
Response times may vary, but founders can expect feedback within a few weeks. Warm introductions are beneficial, especially from mutual connections within the biotech community.
In January 2025, Sound Bioventures participated as a co-lead investor in AnaCardio's $19 million Series A extension, alongside Novo Holdings and Pureos Bioventures. This investment highlights the firm's active role in supporting clinical-stage companies.
Sound Bioventures has been consistently engaged with its portfolio companies, sharing updates on advancements in clinical trials, patent announcements, and grant funding achievements through regular blog posts. This ongoing communication indicates a strong commitment to the biotech community and its portfolio.
What are Sound Bioventures' investment criteria?
Sound Bioventures invests in clinical-stage and about-to-be-clinical private biotherapeutics companies, focusing on specialty therapeutics that address high unmet medical needs. The firm is open to participating in any private financing round, including pre-seed, seed, Series A, B, and C.
How can I pitch to Sound Bioventures?
Founders can reach out via email at info@soundbioventures.com. It is advisable to include a detailed pitch deck outlining the company's vision, product, market potential, and team background.
What makes Sound Bioventures different from other investors?
Sound Bioventures emphasizes investments in novel therapeutic areas, avoiding incremental innovations and focusing on companies that are on the verge of clinical trials. Their strong ties to the Scandinavian biotech ecosystem provide unique advantages in terms of partnerships and resources.
What is the geographic focus of Sound Bioventures?
The firm primarily invests in Europe and the USA, with a particular interest in companies that have Scandinavian roots.
What kind of support does Sound Bioventures provide to its portfolio companies?
Sound Bioventures offers strategic guidance and support throughout the drug development process, leveraging its extensive network to facilitate partnerships and access to resources that can accelerate the path to regulatory approval.
What is the fund size of Sound Bioventures?
The firm has raised a total of €116 million for its first fund, which closed in January 2022.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.